David Stout
Direktor/Vorstandsmitglied bei JABIL INC.
Vermögen: 8 Mio $ am 30.04.2024
Aktive Beziehungen
| Name | Geschlecht | Alter | Unternehmensverbindungen | Zusammenarbeit |
|---|---|---|---|---|
| Jean-Paul Clozel | M | 69 | 25 Jahre | |
| Mark Mondello | M | 60 | 32 Jahre | |
| Andrew C. Weiss | M | 55 | 10 Jahre | |
| Michael Dastoor Dastoor | M | 59 | 24 Jahre | |
| Joshua Schafer | M | 53 | 4 Jahre | |
| Chad D. Costley | M | - |
BlueWillow Biologics, Inc.
 BlueWillow Biologics, Inc. BiotechnologyHealth Technology BlueWillow Biologics, Inc. develops biopharmaceutical products. It offers vaccines targeting respiratory, sexually transmitted, and intranasal immunotherapy for food and respiratory allergies. The company was founded by James R. Baker Jr. and is headquartered in Ann Arbor, MI. | - |
| Kathleen Walters | F | 72 | 12 Jahre | |
| Robert Katz | M | 62 | 8 Jahre | |
| Abraham Noah Oler | M | 48 |
Allos Therapeutics, Inc.
 Allos Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Allos Therapeutics, Inc. is a biopharmaceutical company committed to the development and commercialization of innovative anti-cancer therapeutics. It focuses on the development and commercialization FOLOTYN a pralatrexate injection. FOLOTYN is a folate analogue metabolic inhibitor designed to accumulate preferentially in cancer cells. It targets the inhibition of dihydrofolate reductase, or DHFR, an enzyme critical in the folate pathway, thereby interfering with DNA and RNA synthesis and triggering cancer cell death. Allos Therapeutics is also developing FOLOTYN in other hematologic malignancies and solid tumors. The company was founded on September 1, 1992 and is headquartered in Westminster, CO. | 12 Jahre |
| Martine Clozel | M | 68 | 27 Jahre | |
| Timothy Traud | M | - | 23 Jahre | |
| Bimal Shah | M | 48 |
Allos Therapeutics, Inc.
Allos Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Allos Therapeutics, Inc. is a biopharmaceutical company committed to the development and commercialization of innovative anti-cancer therapeutics. It focuses on the development and commercialization FOLOTYN a pralatrexate injection. FOLOTYN is a folate analogue metabolic inhibitor designed to accumulate preferentially in cancer cells. It targets the inhibition of dihydrofolate reductase, or DHFR, an enzyme critical in the folate pathway, thereby interfering with DNA and RNA synthesis and triggering cancer cell death. Allos Therapeutics is also developing FOLOTYN in other hematologic malignancies and solid tumors. The company was founded on September 1, 1992 and is headquartered in Westminster, CO. | 12 Jahre |
| André Muller | M | 60 | 11 Jahre | |
| Anousheh Ansari | F | 58 | 8 Jahre | |
| Pamela J. Claypool | F | - | 17 Jahre | |
| Alexander Khatuntsev | M | 45 | 17 Jahre | |
| Adam Berry | M | - | 14 Jahre | |
| Fred McCoy | M | - | 2 Jahre | |
| Christopher Holland | M | 58 | 6 Jahre | |
| Jamie Siminoff | M | 47 | - | |
| George G. Arida | M | - |
BlueWillow Biologics, Inc.
BlueWillow Biologics, Inc. BiotechnologyHealth Technology BlueWillow Biologics, Inc. develops biopharmaceutical products. It offers vaccines targeting respiratory, sexually transmitted, and intranasal immunotherapy for food and respiratory allergies. The company was founded by James R. Baker Jr. and is headquartered in Ann Arbor, MI. | 5 Jahre |
| John Plant | M | 70 | 8 Jahre | |
| Kelly P. Justice | M | - | 13 Jahre | |
| Steven Raymund | M | 68 | 28 Jahre | |
| Gary E. Costley | M | 80 |
BlueWillow Biologics, Inc.
BlueWillow Biologics, Inc. BiotechnologyHealth Technology BlueWillow Biologics, Inc. develops biopharmaceutical products. It offers vaccines targeting respiratory, sexually transmitted, and intranasal immunotherapy for food and respiratory allergies. The company was founded by James R. Baker Jr. and is headquartered in Ann Arbor, MI. | - |
| Tiger Tyagarajan | M | 62 | - | |
| Gary Schick | M | - | 6 Jahre | |
| Kristine Melachrino | F | 46 | 17 Jahre | |
| Frank McKay | M | 54 | 5 Jahre | |
| Francis Mckay | M | - | - | |
| Hugo Braun | M | - |
BlueWillow Biologics, Inc.
BlueWillow Biologics, Inc. BiotechnologyHealth Technology BlueWillow Biologics, Inc. develops biopharmaceutical products. It offers vaccines targeting respiratory, sexually transmitted, and intranasal immunotherapy for food and respiratory allergies. The company was founded by James R. Baker Jr. and is headquartered in Ann Arbor, MI. | 9 Jahre |
| May Yap | M | 54 | 10 Jahre | |
| Susanne Dorn | F | - | 6 Jahre | |
| Daryn Smith | M | 54 | 22 Jahre | |
| Jack Appolonia | M | - | 22 Jahre | |
| Edwin Robertson | M | - | 17 Jahre | |
| Jerome Pelletan | M | 54 | 8 Jahre | |
| Ronald J. Stark | M | 60 | 21 Jahre | |
| James E. Cook | M | - | 11 Jahre | |
| Pierre Dufour | M | 68 | 8 Jahre | |
| Susan Wagner-Fleming | F | - | 7 Jahre | |
| Thomas S. Thoman | M | 61 | 23 Jahre | |
| Roberto Ferri | M | 59 | - | |
| François Darchis | M | 68 | 8 Jahre | |
| Michael E. Schick | M | 57 |
Allos Therapeutics, Inc.
Allos Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Allos Therapeutics, Inc. is a biopharmaceutical company committed to the development and commercialization of innovative anti-cancer therapeutics. It focuses on the development and commercialization FOLOTYN a pralatrexate injection. FOLOTYN is a folate analogue metabolic inhibitor designed to accumulate preferentially in cancer cells. It targets the inhibition of dihydrofolate reductase, or DHFR, an enzyme critical in the folate pathway, thereby interfering with DNA and RNA synthesis and triggering cancer cell death. Allos Therapeutics is also developing FOLOTYN in other hematologic malignancies and solid tumors. The company was founded on September 1, 1992 and is headquartered in Westminster, CO. | 15 Jahre |
| Timur Aydin | M | - | - |
Beziehungs-Chart
Beziehungen zu mehreren Unternehmen
Ehemalige Beziehungen
| Name | Geschlecht | Alter | Unternehmensverbindungen | Zusammenarbeit |
|---|---|---|---|---|
| Daniel Cohen | M | - | 13 Jahre | |
| Graham Hetherington | M | 65 | 6 Jahre | |
| Forbes Ian James Alexander | M | 64 | 25 Jahre | |
| Stephen J. Hoffman | M | 70 |
Allos Therapeutics, Inc.
Allos Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Allos Therapeutics, Inc. is a biopharmaceutical company committed to the development and commercialization of innovative anti-cancer therapeutics. It focuses on the development and commercialization FOLOTYN a pralatrexate injection. FOLOTYN is a folate analogue metabolic inhibitor designed to accumulate preferentially in cancer cells. It targets the inhibition of dihydrofolate reductase, or DHFR, an enzyme critical in the folate pathway, thereby interfering with DNA and RNA synthesis and triggering cancer cell death. Allos Therapeutics is also developing FOLOTYN in other hematologic malignancies and solid tumors. The company was founded on September 1, 1992 and is headquartered in Westminster, CO. | 18 Jahre |
| Timothy Main | M | 66 | 34 Jahre | |
| William Burns | M | 76 |
Shire Pharmaceuticals, Inc.
 Shire Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Shire Pharmaceuticals, Inc. manufactures pharmaceutical products. The company offers solutions for attention deficit & hyperactivity disorder, human genetic therapies, gastrointestinal, and renal diseases. The company was founded in 1986 and is headquartered in Wayne, PA | 8 Jahre |
| Jean-Pierre Garnier | M | 75 | 10 Jahre | |
| Richard C. Ill | M | 80 | 10 Jahre | |
| Angus Russell | M | 68 | 14 Jahre | |
| Thomas Sansone | M | 74 | 41 Jahre | |
| Paul Berns | M | 57 |
Allos Therapeutics, Inc.
Allos Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Allos Therapeutics, Inc. is a biopharmaceutical company committed to the development and commercialization of innovative anti-cancer therapeutics. It focuses on the development and commercialization FOLOTYN a pralatrexate injection. FOLOTYN is a folate analogue metabolic inhibitor designed to accumulate preferentially in cancer cells. It targets the inhibition of dihydrofolate reductase, or DHFR, an enzyme critical in the folate pathway, thereby interfering with DNA and RNA synthesis and triggering cancer cell death. Allos Therapeutics is also developing FOLOTYN in other hematologic malignancies and solid tumors. The company was founded on September 1, 1992 and is headquartered in Westminster, CO. | 6 Jahre |
| Susan Kilsby | F | 65 | 8 Jahre | |
| Michael Jacobi | M | 71 | 8 Jahre | |
| Hendrica Verhagen | F | 57 | 2 Jahre | |
| Jean Pierre Malo | M | 69 | 13 Jahre | |
| John C. van Roden | M | 74 | 10 Jahre | |
| Raul Cesan | M | 76 |
Schering Laboratories Advertising, Inc.
Schering-Plough Corp.
 Schering-Plough Corp. Pharmaceuticals: MajorHealth Technology Schering Plough Corp. manufactures and sells pharmaceuticals, consumer and animal health care products. The firm discovers, develops, manufactures and markets advanced drug therapies. The company is headquartered in Kenilworth, NJ. | 9 Jahre |
| James Bowling | M | 56 | 10 Jahre | |
| William Peters | M | 60 | 28 Jahre | |
| Scott Applebaum | M | 57 | 2 Jahre | |
| Kenneth Wilson | M | 59 | 24 Jahre | |
| David Solomon | M | 63 | 2 Jahre | |
| Nishan de Silva | M | 51 |
Allos Therapeutics, Inc.
Allos Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Allos Therapeutics, Inc. is a biopharmaceutical company committed to the development and commercialization of innovative anti-cancer therapeutics. It focuses on the development and commercialization FOLOTYN a pralatrexate injection. FOLOTYN is a folate analogue metabolic inhibitor designed to accumulate preferentially in cancer cells. It targets the inhibition of dihydrofolate reductase, or DHFR, an enzyme critical in the folate pathway, thereby interfering with DNA and RNA synthesis and triggering cancer cell death. Allos Therapeutics is also developing FOLOTYN in other hematologic malignancies and solid tumors. The company was founded on September 1, 1992 and is headquartered in Westminster, CO. | 1 Jahre |
| Cecilia Gonzalo | F | 49 |
Allos Therapeutics, Inc.
Allos Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Allos Therapeutics, Inc. is a biopharmaceutical company committed to the development and commercialization of innovative anti-cancer therapeutics. It focuses on the development and commercialization FOLOTYN a pralatrexate injection. FOLOTYN is a folate analogue metabolic inhibitor designed to accumulate preferentially in cancer cells. It targets the inhibition of dihydrofolate reductase, or DHFR, an enzyme critical in the folate pathway, thereby interfering with DNA and RNA synthesis and triggering cancer cell death. Allos Therapeutics is also developing FOLOTYN in other hematologic malignancies and solid tumors. The company was founded on September 1, 1992 and is headquartered in Westminster, CO. | 1 Jahre |
| Richard L. Bevan | M | - |
Smithkline Beecham Plc
 Smithkline Beecham Plc Pharmaceuticals: OtherHealth Technology Smithkline Beecham Plc develops and manufactures pharmaceutical products. The company markets pharmaceuticals for human and animal healthcare consumption, vaccines, over the counter medicines, health related consumer products, clinical laboratory testing services, disease management and pharmaceutical benefit management. It is headquartered in Brentford, UK. | 16 Jahre |
| Mitchell Glass | M | - |
GlaxoSmithKline LLC
 GlaxoSmithKline LLC Pharmaceuticals: MajorHealth Technology GlaxoSmithKline LLC engages in discovering, developing, and delivering medicines, vaccines, and other healthcare products. It offers prescription medicines that treat various diseases, including cancer, HIV/AIDS, depression, diabetes, high blood pressure, herpes, asthma, migraine, and heart diseases, as well as stomach and skin problems, infections, and flu. It also provides vaccines for children and adults; and over-the-counter products. The company was founded in 1929 and is headquartered in Philadelphia, PA. | 1 Jahre |
| Howard Mayer | M | 62 |
Shire Pharmaceuticals, Inc.
Shire Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Shire Pharmaceuticals, Inc. manufactures pharmaceutical products. The company offers solutions for attention deficit & hyperactivity disorder, human genetic therapies, gastrointestinal, and renal diseases. The company was founded in 1986 and is headquartered in Wayne, PA | 6 Jahre |
| Mark McHale | M | 59 |
Smithkline Beecham Plc
Smithkline Beecham Plc Pharmaceuticals: OtherHealth Technology Smithkline Beecham Plc develops and manufactures pharmaceutical products. The company markets pharmaceuticals for human and animal healthcare consumption, vaccines, over the counter medicines, health related consumer products, clinical laboratory testing services, disease management and pharmaceutical benefit management. It is headquartered in Brentford, UK.
GlaxoSmithKline LLC
GlaxoSmithKline LLC Pharmaceuticals: MajorHealth Technology GlaxoSmithKline LLC engages in discovering, developing, and delivering medicines, vaccines, and other healthcare products. It offers prescription medicines that treat various diseases, including cancer, HIV/AIDS, depression, diabetes, high blood pressure, herpes, asthma, migraine, and heart diseases, as well as stomach and skin problems, infections, and flu. It also provides vaccines for children and adults; and over-the-counter products. The company was founded in 1929 and is headquartered in Philadelphia, PA. | 6 Jahre |
| Robert Harrell | M | - |
Shire Pharmaceuticals, Inc.
Shire Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Shire Pharmaceuticals, Inc. manufactures pharmaceutical products. The company offers solutions for attention deficit & hyperactivity disorder, human genetic therapies, gastrointestinal, and renal diseases. The company was founded in 1986 and is headquartered in Wayne, PA | 8 Jahre |
| Thomas Luby | M | - |
Shire Pharmaceuticals, Inc.
Shire Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Shire Pharmaceuticals, Inc. manufactures pharmaceutical products. The company offers solutions for attention deficit & hyperactivity disorder, human genetic therapies, gastrointestinal, and renal diseases. The company was founded in 1986 and is headquartered in Wayne, PA | 3 Jahre |
| William D. Morean | M | 68 | 36 Jahre | |
| Lawrence J. Murphy | M | 81 | 27 Jahre | |
| Frank Newman | M | 75 | 20 Jahre | |
| Hugh A. D'Andrade | M | 85 |
Schering-Plough Corp.
Schering-Plough Corp. Pharmaceuticals: MajorHealth Technology Schering Plough Corp. manufactures and sells pharmaceuticals, consumer and animal health care products. The firm discovers, develops, manufactures and markets advanced drug therapies. The company is headquartered in Kenilworth, NJ. | 4 Jahre |
| Lee Muller Thomas | M | 79 | 18 Jahre | |
| William D. Muir | M | 55 | 25 Jahre | |
| Beth A. Walters | F | - | 27 Jahre | |
| Dean A. Bertolino | M | 55 | - | |
| Robert McLaughlin | M | 67 | 15 Jahre | |
| Matthew Emmens | M | 72 | 11 Jahre | |
| Marc H. Graboyes | M | 54 |
Allos Therapeutics, Inc.
Allos Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Allos Therapeutics, Inc. is a biopharmaceutical company committed to the development and commercialization of innovative anti-cancer therapeutics. It focuses on the development and commercialization FOLOTYN a pralatrexate injection. FOLOTYN is a folate analogue metabolic inhibitor designed to accumulate preferentially in cancer cells. It targets the inhibition of dihydrofolate reductase, or DHFR, an enzyme critical in the folate pathway, thereby interfering with DNA and RNA synthesis and triggering cancer cell death. Allos Therapeutics is also developing FOLOTYN in other hematologic malignancies and solid tumors. The company was founded on September 1, 1992 and is headquartered in Westminster, CO. | 8 Jahre |
| Daniel E. Greenleaf | M | 59 |
Schering-Plough Corp.
Schering-Plough Corp. Pharmaceuticals: MajorHealth Technology Schering Plough Corp. manufactures and sells pharmaceuticals, consumer and animal health care products. The firm discovers, develops, manufactures and markets advanced drug therapies. The company is headquartered in Kenilworth, NJ. | 10 Jahre |
| Richard Kogan | M | 81 |
Schering-Plough Corp.
Schering-Plough Corp. Pharmaceuticals: MajorHealth Technology Schering Plough Corp. manufactures and sells pharmaceuticals, consumer and animal health care products. The firm discovers, develops, manufactures and markets advanced drug therapies. The company is headquartered in Kenilworth, NJ. | 21 Jahre |
| Mel Lavitt | M | 86 | 25 Jahre | |
| Jeffrey Leiden | M | 68 |
Shire Pharmaceuticals, Inc.
Shire Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Shire Pharmaceuticals, Inc. manufactures pharmaceutical products. The company offers solutions for attention deficit & hyperactivity disorder, human genetic therapies, gastrointestinal, and renal diseases. The company was founded in 1986 and is headquartered in Wayne, PA | 6 Jahre |
| Robert Alexander Ingram | M | 81 |
GlaxoSmithKline LLC
GlaxoSmithKline LLC Pharmaceuticals: MajorHealth Technology GlaxoSmithKline LLC engages in discovering, developing, and delivering medicines, vaccines, and other healthcare products. It offers prescription medicines that treat various diseases, including cancer, HIV/AIDS, depression, diabetes, high blood pressure, herpes, asthma, migraine, and heart diseases, as well as stomach and skin problems, infections, and flu. It also provides vaccines for children and adults; and over-the-counter products. The company was founded in 1929 and is headquartered in Philadelphia, PA. | 9 Jahre |
| Bob Lumpkins | M | 80 | 3 Jahre | |
| Paula Sneed | F | 76 | 17 Jahre | |
| Joseph Turner | M | 72 |
Allos Therapeutics, Inc.
Allos Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Allos Therapeutics, Inc. is a biopharmaceutical company committed to the development and commercialization of innovative anti-cancer therapeutics. It focuses on the development and commercialization FOLOTYN a pralatrexate injection. FOLOTYN is a folate analogue metabolic inhibitor designed to accumulate preferentially in cancer cells. It targets the inhibition of dihydrofolate reductase, or DHFR, an enzyme critical in the folate pathway, thereby interfering with DNA and RNA synthesis and triggering cancer cell death. Allos Therapeutics is also developing FOLOTYN in other hematologic malignancies and solid tumors. The company was founded on September 1, 1992 and is headquartered in Westminster, CO. | - |
| Timothy Patrick Lynch | M | 54 |
Allos Therapeutics, Inc.
Allos Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Allos Therapeutics, Inc. is a biopharmaceutical company committed to the development and commercialization of innovative anti-cancer therapeutics. It focuses on the development and commercialization FOLOTYN a pralatrexate injection. FOLOTYN is a folate analogue metabolic inhibitor designed to accumulate preferentially in cancer cells. It targets the inhibition of dihydrofolate reductase, or DHFR, an enzyme critical in the folate pathway, thereby interfering with DNA and RNA synthesis and triggering cancer cell death. Allos Therapeutics is also developing FOLOTYN in other hematologic malignancies and solid tumors. The company was founded on September 1, 1992 and is headquartered in Westminster, CO. | 6 Jahre |
| Philippe Chambon | M | 65 | - | |
| Ted B. Miller | M | 71 | 6 Jahre | |
| Katharine Knobil | M | 60 |
GlaxoSmithKline LLC
GlaxoSmithKline LLC Pharmaceuticals: MajorHealth Technology GlaxoSmithKline LLC engages in discovering, developing, and delivering medicines, vaccines, and other healthcare products. It offers prescription medicines that treat various diseases, including cancer, HIV/AIDS, depression, diabetes, high blood pressure, herpes, asthma, migraine, and heart diseases, as well as stomach and skin problems, infections, and flu. It also provides vaccines for children and adults; and over-the-counter products. The company was founded in 1929 and is headquartered in Philadelphia, PA. | 21 Jahre |
Statistik
| Land | Beziehungen | % des Gesamten |
|---|---|---|
| Vereinigte Staaten | 78 | 78,79% |
| Schweiz | 9 | 9,09% |
| Irland | 8 | 8,08% |
| Frankreich | 5 | 5,05% |
| Vereinigtes Königreich | 2 | 2,02% |
Alter der Beziehungen
Aktive
Vergangene
Herr
Frau
Aufsichtsräte
Führungskräfte
Ursprung der Beziehungen
- Börse
- Insiders
- David Stout
- Persönliches Netzwerk
